Crossmark

Utility of a recurrence prediction tool (DASH score) at a single centre after unprovoked venous thromboembolism: patient uptake of the tool and short term risks of stopping anticoagulation

Crossref DOI link: https://doi.org/10.1007/s11239-021-02382-x

Published Online: 2021-02-02

Published Print: 2021-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Thomas, W. https://orcid.org/0000-0001-6969-3173
License Information

Text and Data Mining valid from 2021-02-02

Version of Record valid from 2021-02-02
More Information

Article History

Accepted: 10 January 2021

First Online: 2 February 2021

Compliance with ethical standards

:

: WT—speakers fees from Pfizer, Bayer, Sobi and Takeda. Advisory boards for Daiichi-Sankyo, Sanofi and Ablynx.

: This project was registered and approved as a service evaluation with the Trust audit department (PRN 7124).

Document is current

Any future updates will be listed below